Bradley's Pamine Promotional Claims On GI Motility Draw FDA Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency's ad division cites promotional materials that suggest the peptic ulcer agent is effective in treating symptoms such as diarrhea, cramping and bloating. FDA requests Bradley disseminate materials correcting violative claims in a product website, professional sales aid and patient brochure.
You may also be interested in...
Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.
Astellas Ends Aczone Acne Treatment Collaboration Agreement With QLT
QLT now has worldwide marketing rights to the topical acne treatment. Astellas believes labeling proposed by FDA will limit the market profile for Aczone, the company said. Aczone’s user fee deadline is July 7.
Omnicare Boosts Specialty Pharma Services With $235 Mil. RxCrossroads Buy
Acquisition will enable company to leverage "end-to-end" product development through post-commercialization offerings, company says. Omnicare is now in discussions with NeighborCare after raising its takeover bid to $1.55 bil.